

Camillio Porta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8335732/publications.pdf>

Version: 2024-02-01

381
papers

36,559
citations

25034

57
h-index

3487

182
g-index

392
all docs

392
docs citations

392
times ranked

32523
citing authors

#	ARTICLE	IF	CITATIONS
1	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	2.0	7
2	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	1.9	33
3	Renal cell carcinoma and viral infections: A dangerous relationship?. <i>World Journal of Nephrology</i> , 2022, 11, 1-12.	2.0	1
4	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	3.2	10
5	Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 285-295.	1.9	5
6	Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3826.	4.1	31
7	SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations—consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM). <i>Radiologia Medica</i> , 2022, 127, 534-542.	7.7	8
8	Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. <i>Cancer Treatment Reviews</i> , 2022, 105, 102379.	7.7	9
9	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	4.1	103
10	Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma. <i>Cells</i> , 2022, 11, 17.	4.1	7
11	Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4173.	4.1	40
12	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.	10.7	23
13	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	2.5	3
14	Redistribution of CD8 ⁺ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 597-605.	1.5	2
15	Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma: The "retrial" study from the Italian Group of Onco-Nephrology (G.I.O.N.). <i>Journal of Onco-Nephrology</i> , 2022, 6, 107-114.	0.6	1
16	Abemaciclib for malignant pleural mesothelioma. <i>Lancet Oncology</i> , The, 2022, 23, e237.	10.7	2
17	Psychosocial impact of COVID-19 pandemic on cancer patients with bone metastases (PsyCO-B): a multicentre prospective observational study. <i>Bone Reports</i> , 2022, 16, 101371.	0.4	0
18	The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (1 st -Meet-URO analysis).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4534-4534.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	10.7	114
20	Cabozantinib for the treatment of solid tumors: a systematic review. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211071.	3.2	17
21	Maturation of overall survival (OS) in TIVO-3 with long-term follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4557-4557.	1.6	2
22	Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2022, 172, 191-198.	2.8	8
23	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.	1.9	64
24	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e84-e91.	1.9	23
25	Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art. <i>Journal of Bone Oncology</i> , 2021, 26, 100337.	2.4	6
26	Preventive strategies for acute kidney injury in cancer patients. CKJ: <i>Clinical Kidney Journal</i> , 2021, 14, 70-83.	2.9	28
27	A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1667-1678.	4.2	27
28	Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. <i>European Urology Oncology</i> , 2021, 4, 274-281.	5.4	7
29	Second-line treatment in renal cell carcinoma: clinical experience and decision making. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110228.	2.0	6
30	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	5.9	104
31	TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib.. <i>Journal of Clinical Oncology</i> , 2021, 39, 278-278.	1.6	2
32	First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. <i>ESMO Open</i> , 2021, 6, 100030.	4.5	35
33	The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 339-339.	1.6	6
34	Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).. <i>Journal of Clinical Oncology</i> , 2021, 39, 269-269.	1.6	21
35	Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313.	1.6	8
36	Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.. <i>Journal of Clinical Oncology</i> , 2021, 39, 308-308.	1.6	48

#	ARTICLE	IF	CITATIONS
37	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	27.0	961
38	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. Cancer Treatment Reviews, 2021, 94, 102157.	7.7	16
39	Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. Current Opinion in Urology, 2021, 31, 236-241.	1.8	4
40	Targeted RNA-seq signature of breast cancer (BC) circulating tumor cells (CTCs) correlates with the onset of bone-only metastases. Bone Reports, 2021, 14, 100840.	0.4	0
41	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	27.0	956
42	Prognostic Factors and Current Treatment Strategies for Renal Cell Carcinoma Metastatic to the Brain: An Overview. Cancers, 2021, 13, 2114.	3.7	12
43	The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice. Genes, 2021, 12, 727.	2.4	29
44	Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management. Kidney Cancer, 2021, 5, 93-106.	0.4	0
45	Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers, 2021, 13, 3091.	3.7	16
46	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6813.	4.1	20
47	Uterine carcinosarcoma: An overview. Critical Reviews in Oncology/Hematology, 2021, 163, 103369.	4.4	16
48	Primary Soft Tissue Sarcoma of the Heart: An Emerging Chapter in Cardio-Oncology. Biomedicines, 2021, 9, 774.	3.2	9
49	Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. Cancers, 2021, 13, 3968.	3.7	9
50	Sorafenib and hepatocellular carcinoma: is alpha-fetoprotein a biomarker predictive of tumor biology and primary resistance?. Future Oncology, 2021, 17, 3579-3584.	2.4	2
51	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. European Journal of Cancer, 2021, 155, 56-63.	2.8	8
52	Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?. Oncology Reviews, 2021, 15, 564.	1.8	4
53	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. Translational Oncology, 2021, 14, 101153.	3.7	5
54	The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. Journal of Neuroendocrinology, 2021, 33, e13041.	2.6	3

#	ARTICLE	IF	CITATIONS
55	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. <i>Microvascular Research</i> , 2021, 138, 104189.	2.5	11
56	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. <i>Cancer Treatment Reviews</i> , 2021, 100, 102288.	7.7	9
57	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	3.2	36
58	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110543.	2.0	3
59	Renal Cancer. <i>UNIPA Springer Series</i> , 2021, , 755-774.	0.1	1
60	Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors. <i>Cancer Management and Research</i> , 2021, Volume 13, 7623-7636.	1.9	6
61	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-9.	3.3	5
62	Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 441-450.	3.2	2
63	An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the "Pamerit" study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 484-491.	1.3	1
64	Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 8598-8610.	0.0	1
65	Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFIT) for measuring financial toxicity of cancer within a public healthcare system. <i>BMJ Open</i> , 2021, 11, e049128.	1.9	12
66	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1037-1046.	2.3	2
67	RAMES study: is there really a role for VEGF inhibition in mesothelioma?. <i>Lancet Oncology, The</i> , 2021, 22, e532.	10.7	3
68	A Glimpse in the Future of Malignant Mesothelioma Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 809337.	3.5	2
69	Vitamin K effects in human health: new insights beyond bone and cardiovascular health. <i>Journal of Nephrology</i> , 2020, 33, 239-249.	2.0	44
70	Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.	1.9	52
71	Conventional chemotherapy. , 2020, , 127-153.e11.		3
72	Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. <i>Lancet Oncology, The</i> , 2020, 21, 95-104.	10.7	160

#	ARTICLE	IF	CITATIONS
73	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2020, 12, 84.	3.7	22
74	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
75	The basics of onco-nephrology in the renal clinic. <i>Journal of Nephrology</i> , 2020, 33, 1143-1149.	2.0	3
76	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.	4.5	343
77	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3583.	3.7	16
78	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	5.2	8
79	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. <i>Oncolimmunology</i> , 2020, 9, 1832348.	4.6	55
80	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5394.	4.1	83
81	Patients with sarcomatoid renal cell carcinoma “re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 136, 195-203.	2.8	47
82	An updated cost-effectiveness analysis of pazopanib versus sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma in Italy. <i>Journal of Medical Economics</i> , 2020, 23, 1579-1587.	2.1	4
83	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852.	4.5	18
84	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	5.2	26
85	Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581130.	2.8	7
86	An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2199-2204.	1.8	3
87	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	10.7	324
88	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 783-785.	1.9	20
89	Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data. <i>Journal of Onco-Nephrology</i> , 2020, 4, 153-164.	0.6	0
90	Large Extracellular Vesicles “A New Frontier of Liquid Biopsy in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6543.	4.1	17

#	ARTICLE	IF	CITATIONS
91	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2020, 19, 1329-1338.	2.4	64
92	Exploring the Spectrum of Kidney Ciliopathies. Diagnostics, 2020, 10, 1099.	2.6	8
93	Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma. Metabolites, 2020, 10, 509.	2.9	51
94	738P Soluble PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTN2A1 as predictive biomarkers of nivolumab response in patients with metastatic clear cell renal carcinoma. Annals of Oncology, 2020, 31, S575.	1.2	0
95	Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. Oncoimmunology, 2020, 9, 1846901.	4.6	27
96	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. Frontiers in Immunology, 2020, 11, 574271.	4.8	112
97	Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Tumori, 2020, 106, 257-266.	1.1	2
98	Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system. ESMO Open, 2020, 5, e000790.	4.5	3
99	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. Clinical Genitourinary Cancer, 2020, 18, 477-488.	1.9	15
100	Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score. Clinical Genitourinary Cancer, 2020, 18, e588-e597.	1.9	11
101	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. Frontiers in Immunology, 2020, 11, 490.	4.8	38
102	Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology, 2020, 52, 297-309.	0.6	35
103	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	5.4	29
104	Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treatment Reviews, 2020, 84, 101966.	7.7	44
105	Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open, 2020, 5, e000618.	4.5	9
106	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors. , 2020, , 299-306.e1.		0
107	TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2020, 38, 5062-5062.	1.6	3
108	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 5071-5071.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2020, 38, 609-609.	1.6	51
110	Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. Journal of Clinical Oncology, 2020, 38, 632-632.	1.6	0
111	MP14-12â€fSTEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR TREATMENT OF RENAL CELL CARCINOMA (RCC) WITH INFERIOR VENA CAVA TUMOR THROMBUS (IVC-TT). Journal of Urology, 2020, 203, .	0.4	0
112	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. Journal of Clinical Oncology, 2020, 38, 5070-5070.	1.6	0
113	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2020, 38, 642-642.	1.6	9
114	Abstract P1-17-09: Cardiotoxicity and overall safety profile of adjuvant chemotherapy in elderly breast cancer patients: A cohort study. , 2020, , .		0
115	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: realâ€world results from an expanded access programme. BJU International, 2019, 123, 98-105.	2.5	70
116	Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review. Critical Reviews in Oncology/Hematology, 2019, 139, 149-157.	4.4	10
117	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	10.7	594
118	Toward a genome-based treatment landscape for renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2019, 142, 141-152.	4.4	15
119	Renal cell carcinoma treatment after first-line combinations. Lancet Oncology, The, 2019, 20, 1332-1334.	10.7	8
120	Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. International Journal of Molecular Sciences, 2019, 20, 3951.	4.1	62
121	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e903-e908.	1.9	30
122	Intracellular Chloride Ion Channel Protein-1 Expression in Clear Cell Renal Cell Carcinoma. Cancer Genomics and Proteomics, 2019, 16, 299-307.	2.0	16
123	Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2019, 105, 3-12.	1.1	10
124	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111â€28. European Urology Oncology, 2019, 2, 603-604.	5.4	1
125	Drug resistance in papillary RCC: from putative mechanisms to clinical practicalities. Nature Reviews Urology, 2019, 16, 655-673.	3.8	24
126	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	4.4	7

#	ARTICLE	IF	CITATIONS
127	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	1.9	71
128	Metastatic renal cell carcinoma cells growing in 3D on poly-L-lysine or laminin present a stem-like phenotype and drug resistance. <i>Oncology Reports</i> , 2019, 42, 1878-1892.	2.6	12
129	Targeting angiogenesis in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 245-257.	2.4	12
130	Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right Patient. <i>Hepatology</i> , 2019, 70, 429-430.	7.3	3
131	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	2.4	40
132	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
133	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Società Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51.	4.4	11
134	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	13.7	778
135	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	2.5	32
136	THU-482-A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 70, e373.	3.7	1
137	Immune-based combination therapy for metastatic kidney cancer. <i>Nature Reviews Nephrology</i> , 2019, 15, 324-325.	9.6	3
138	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
139	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	9.6	68
140	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019, 11, 631-643.	2.0	38
141	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. , 2019, 7, 99.		110
142	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 529.e1-529.e7.	1.6	5
143	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	1.9	11
144	Acute Kidney Injury in Oncology and Tumor Lysis Syndrome. , 2019, , 234-250.e1.		1

#	ARTICLE	IF	CITATIONS
145	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	3.7	34
146	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	5.4	31
147	Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1165-1179.	7.3	48
148	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells. <i>Cytotechnology</i> , 2019, 71, 149-163.	1.6	17
149	Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 143-148.	4.4	10
150	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. <i>Journal of Nephrology</i> , 2019, 32, 57-64.	2.0	16
151	Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4512-4512.	1.6	30
152	TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4572-4572.	1.6	1
153	Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4575-4575.	1.6	4
154	Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.	1.6	49
155	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	1.6	10
156	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	1.6	14
157	Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?. <i>Annals of Translational Medicine</i> , 2019, 7, S15-S15.	1.7	1
158	Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14054-e14054.	1.6	0
159	A novel predictive biomarker of immunotherapy response in metastatic renal cell carcinoma (mRCC): The lymphocyte microRNA expression profile.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16109-e16109.	1.6	0
160	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693.	10.7	285
161	Acute Kidney Injury in Cancer Patients. <i>Contributions To Nephrology</i> , 2018, 193, 137-148.	1.1	18
162	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	27.0	3,334

#	ARTICLE	IF	CITATIONS
163	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma". According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. Pathology and Oncology Research, 2018, 24, 447-456.	1.9	20
164	Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. Clinical Genitourinary Cancer, 2018, 16, 6-12.e4.	1.9	11
165	Urothelial cancer: Once there were urologists, now oncologists joined, what about nephrologists?. Journal of Onco-Nephrology, 2018, 2, 3-5.	0.6	3
166	Opening an onconeurology clinic: recommendations and basic requirements. Nephrology Dialysis Transplantation, 2018, 33, 1503-1510.	0.7	31
167	Costo-Efficacia di cabozantinib nel trattamento di seconda linea del tumore a cellule renali metastatico (mRCC) in Italia. Global & Regional Health Technology Assessment, 2018, 2018, 228424031879073.	0.1	0
168	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review. Critical Reviews in Oncology/Hematology, 2018, 132, 89-99.	4.4	24
169	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.	4.1	53
170	Should CARMENA Really Change our Attitude Towards Cyto-reductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cyto-reductive Nephrectomy in the Era of Targeted Therapy. Targeted Oncology, 2018, 13, 705-714.	3.6	35
171	Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. Future Oncology, 2018, 14, 1347-1354.	2.4	9
172	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. Clinical Genitourinary Cancer, 2018, 16, 355-359.e1.	1.9	31
173	The role of tivozanib in advanced renal cell carcinoma therapy. Expert Review of Anticancer Therapy, 2018, 18, 1113-1124.	2.4	14
174	Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis. Cancer Treatment Reviews, 2018, 70, 112-117.	7.7	17
175	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer, 2018, 2, 31-36.	0.4	10
176	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. Anti-Cancer Drugs, 2018, 29, 705-709.	1.4	2
177	Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Journal of Nephrology, 2017, 30, 171-180.	2.0	38
178	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 39-43.	1.2	8
179	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 205-216.	1.8	5
180	How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2017, 17, 227-233.	2.4	18

#	ARTICLE	IF	CITATIONS
181	Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective. <i>Clinical Therapeutics</i> , 2017, 39, 567-580.e2.	2.5	20
182	Editorial Comment from Dr Porta <i>et al</i> . to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the <sc>USA</sc>. <i>International Journal of Urology</i> , 2017, 24, 279-280.	1.0	0
183	Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. <i>BJU International</i> , 2017, 119, 846-853.	2.5	3
184	Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 151-162.	3.1	4
185	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017, 60, 152-157.	7.7	35
186	CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. <i>British Journal of Cancer</i> , 2017, 117, 947-953.	6.4	27
187	Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. <i>Therapeutic Advances in Urology</i> , 2017, 9, 195-207.	2.0	47
188	Renin angiotensin system deregulation as renal cancer risk factor (Review). <i>Oncology Letters</i> , 2017, 14, 5059-5068.	1.8	35
189	Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. <i>Frontiers in Pharmacology</i> , 2017, 8, 329.	3.5	5
190	Introduction to the Journal of Onco-Nephrology. <i>Journal of Onco-Nephrology</i> , 2017, 1, 1-4.	0.6	9
191	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017, 8, 7328-7335.	1.8	19
192	Mammalian Targets of Rapamycin Inhibitors: Temsirolimus and Everolimus. , 2017, , 273-294.		1
193	Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 14408-14415.	1.8	30
194	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2017, 23, 2448.	3.3	10
195	Insulin-like growth factor-1 signaling in renal cell carcinoma. <i>BMC Cancer</i> , 2016, 16, 453.	2.6	49
196	Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. <i>PLoS ONE</i> , 2016, 11, e0151662.	2.5	56
197	Endoplasmic Reticulum Ca^{2+} Handling and Apoptotic Resistance in Tumor-Derived Endothelial Colony Forming Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2260-2271.	2.6	24
198	Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. <i>Future Oncology</i> , 2016, 12, 533-549.	2.4	8

#	ARTICLE	IF	CITATIONS
199	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2016, 34, 2429-2430.	1.6	5
200	Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. <i>European Journal of Cancer</i> , 2016, 69, 226-235.	2.8	65
201	Choosing the right cell line for renal cell cancer research. <i>Molecular Cancer</i> , 2016, 15, 83.	19.2	205
202	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	1.9	8
203	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	3.6	152
204	Transplantation of kidneys with tumors. <i>Journal of Nephrology</i> , 2016, 29, 163-168.	2.0	9
205	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	7.0	193
206	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 254-263.	4.4	2
207	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016, 11, 345-351.	3.6	56
208	Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 643-655.	1.8	10
209	Glomerular diseases and cancer: evaluation of underlying malignancy. <i>Journal of Nephrology</i> , 2016, 29, 143-152.	2.0	45
210	Onco-nephrology: a decalogue: Table 1.. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 515-519.	0.7	63
211	Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.	1.9	53
212	Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. <i>Oncotarget</i> , 2016, 7, 72622-72633.	1.8	60
213	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	1.8	11
214	ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. <i>Annals of Translational Medicine</i> , 2016, 4, S14-S14.	1.7	16
215	Long-term safety of targeted agents used to treat metastatic renal cell carcinoma: the issue is not the rate of adverse events over time, but the expertise needed to manage them. <i>Translational Cancer Research</i> , 2016, 5, S613-S615.	1.0	1
216	Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy. <i>Current Medicinal Chemistry</i> , 2016, 23, 3450-3480.	2.4	55

#	ARTICLE	IF	CITATIONS
217	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015, 26, 2392-2398.	1.2	25
218	Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. <i>Future Oncology</i> , 2015, 11, 3159-3166.	2.4	10
219	The role of the cell-cell interactions in cancer progression. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 283-296.	3.6	89
220	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. <i>Tumori</i> , 2015, 101, 139-143.	1.1	6
221	Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3219-3220.	1.6	4
222	Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. <i>Liver International</i> , 2015, 35, 2001-2008.	3.9	49
223	Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. <i>Future Oncology</i> , 2015, 11, 39-50.	2.4	48
224	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 10.	8.6	65
225	Renal effects of targeted anticancer therapies. <i>Nature Reviews Nephrology</i> , 2015, 11, 354-370.	9.6	95
226	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	1.5	72
227	Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 287-294.	1.9	40
228	Renal cancer in kidney transplanted patients. <i>Journal of Nephrology</i> , 2015, 28, 659-668.	2.0	38
229	Tivantinib (ARQ197) in hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 615-622.	2.4	16
230	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	3.6	49
231	Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial. <i>Oncology</i> , 2015, 88, 273-280.	1.9	24
232	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma—Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015, 20, 1028-1035.	3.7	23
233	Renal toxicity of anticancer agents targeting HER2 and EGFR. <i>Journal of Nephrology</i> , 2015, 28, 647-657.	2.0	33
234	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 50-59.	4.4	14

#	ARTICLE	IF	CITATIONS
235	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 41-47.	0.4	58
236	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	1.9	122
237	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	2.5	9
238	Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. <i>Current Drug Targets</i> , 2015, 16, 164-170.	2.1	47
239	Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. , 2015, , 555-575.		0
240	Predicting efficacy of sunitinib in metastatic renal cell carcinoma. <i>Current Biomarker Findings</i> , 2014, , 43.	0.4	0
241	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.9	43
242	Store-Operated Ca ²⁺ Entry Does Not Control Proliferation in Primary Cultures of Human Metastatic Renal Cellular Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-19.	1.9	51
243	Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. <i>Future Oncology</i> , 2014, 10, 1741-1750.	2.4	12
244	Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. <i>Cancer Medicine</i> , 2014, 3, 1517-1526.	2.8	53
245	Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- γ (IFN- γ) in Operable Renal Cell Carcinoma (RCC). <i>Journal of Immunotherapy</i> , 2014, 37, 440-447.	2.4	61
246	Reply to S. Barni et al and M. Sun et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3783-3784.	1.6	1
247	Targeting PI3K/Akt/mTOR Signaling in Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 64.	2.8	1,077
248	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 262-269.	1.9	9
249	Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1412-1418.	1.6	381
250	Slow and Steady Wins the Race: Practical (and Philosophical) Considerations of Treatment Activity Evaluation When Novel Anticancer Agents Just Slow Neoplastic Progression. <i>European Urology</i> , 2014, 65, 721-722.	1.9	0
251	Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 1-12.	1.9	7
252	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	10.7	239

#	ARTICLE	IF	CITATIONS
253	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014, 44, 5-16.	3.3	31
254	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , 2014, 1, 181-188.	4.2	16
255	Adjuvant Treatment for Resected Renal Cell Carcinoma: Are All Strategies Equally Negative? Potential Implications for Trial Design With Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 471-476.	1.9	22
256	Evidence and experience for the management of metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , Supplement, 2013, 11, 1-8.	2.2	3
257	Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). <i>European Urology</i> , 2013, 63, 254-261.	1.9	29
258	Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 55-63.	10.7	522
259	Axitinib dose titration: what's the limiting factor?. <i>Lancet Oncology</i> , The, 2013, 14, 1152-1154.	10.7	6
260	Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. <i>Future Oncology</i> , 2013, 9, 831-843.	2.4	7
261	Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients. <i>Oncology</i> , 2013, 84, 115-122.	1.9	77
262	From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 813-815.	3.1	0
263	Case Report: Long-Lasting Response in a Patient with Metastatic Renal Cell Cancer Receiving Antitumor Cytotoxic T Lymphocytes. <i>Tumori</i> , 2013, 99, e282-e284.	1.1	1
264	Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e83026.	2.5	66
265	Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. <i>Anticancer Research</i> , 2013, 33, 3487-94.	1.1	53
266	A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. <i>Anticancer Research</i> , 2013, 33, 4999-5004.	1.1	3
267	Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1089-1096.	2.4	5
268	A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. <i>Oncology</i> , 2012, 82, 333-340.	1.9	29
269	Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study. <i>Future Oncology</i> , 2012, 8, 1605-1612.	2.4	13
270	The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. <i>Future Oncology</i> , 2012, 8, 1051-1057.	2.4	11

#	ARTICLE	IF	CITATIONS
271	How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. <i>European Urology</i> , 2012, 62, 1020-1021.	1.9	15
272	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829.	3.7	736
273	Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. <i>Cancer Treatment Reviews</i> , 2012, 38, 127-132.	7.7	9
274	Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. <i>European Journal of Cancer</i> , 2012, 48, 2983-2992.	2.8	30
275	mRCC management: past, present and future. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 1-11.	2.2	1
276	Treatment selection in metastatic renal cell carcinoma: expert consensus. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 327-337.	27.6	121
277	Sequential therapy in metastatic renal cell carcinoma: what comes next?. <i>Medical Oncology</i> , 2012, 29, 1914-1915.	2.5	1
278	Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1571-1577.	2.4	35
279	Store-Operated Ca ²⁺ Entry Is Remodelled and Controls In Vitro Angiogenesis in Endothelial Progenitor Cells Isolated from Tumoral Patients. <i>PLoS ONE</i> , 2012, 7, e42541.	2.5	121
280	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: A critical review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 323-337.	4.4	31
281	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.	1.9	59
282	Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud's Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-833. <i>European Urology</i> , 2012, 62, e7-e8.	1.9	0
283	SORAFENIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA. <i>BJU International</i> , 2012, 110, E235.	2.5	5
284	Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. <i>BJU International</i> , 2012, 110, 692-698.	2.5	39
285	Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) – PISCES study, NCT 01064310. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA4502-CRA4502.	1.6	27
286	Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial. <i>Translational Andrology and Urology</i> , 2012, 1, 120-2.	1.4	1
287	Optimizing treatment for metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1901-1911.	2.4	4
288	Bevacizumab plus Interferon- γ versus Sunitinib for First-Line Treatment of Renal Cell Carcinoma in Italy. <i>Clinical Drug Investigation</i> , 2011, 31, 507-517.	2.2	12

#	ARTICLE	IF	CITATIONS
289	Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.	2.8	133
290	Management Of Tyrosine Kinase Inhibitorâ€“Induced Handâ€“Foot Skin Reaction: Viewpoints from the Medical Oncologist, Dermatologist, and Oncology Nurse. <i>The Journal of Supportive Oncology</i> , 2011, 9, 13-23.	2.3	36
291	Indirect treatment comparison of bevacizumab + interferon- α -2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. <i>ClinicoEconomics and Outcomes Research</i> , 2011, 3, 19.	1.9	5
292	Immunological Effects of Multikinase Inhibitors for Kidney Cancer: A Clue for Integration with Cellular Therapies?. <i>Journal of Cancer</i> , 2011, 2, 333-338.	2.5	39
293	Receptor Activator of NF- κ B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients. <i>PLoS ONE</i> , 2011, 6, e19234.	2.5	157
294	Surgery and Target Agents for Renal Cell Carcinoma Treatment: The Path between Proper Interaction. <i>Urologia</i> , 2011, 78, 9-15.	0.7	0
295	A new patientâ€“focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. <i>BJU International</i> , 2011, 107, 1190-1199.	2.5	21
296	TREATMENT OF METASTATIC RENAL CARCINOMA PATIENTS WITH THE COMBINATION OF GEMCITABINE, CAPECITABINE AND BEVACIZUMAB AT A TERTIARY CANCER CENTRE. <i>BJU International</i> , 2011, 107, 747-748.	2.5	3
297	Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. <i>BJU International</i> , 2011, 108, E250-E257.	2.5	79
298	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. <i>European Urology</i> , 2011, 59, 526-540.	1.9	119
299	Entropy Increases in Kidney Cancer Treatment, but a Bit of Simplicity May Emerge From Chaos. <i>European Urology</i> , 2011, 60, 1171-1172.	1.9	6
300	Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time. <i>Oncology Reviews</i> , 2011, 5, 141-142.	1.8	0
301	Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. <i>BMC Cancer</i> , 2011, 11, 105.	2.6	34
302	Expression pattern of receptor activator of NF- κ B (RANK) in a series of primary solid tumors and related bone metastases. <i>Journal of Cellular Physiology</i> , 2011, 226, 780-784.	4.1	118
303	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	4.1	126
304	Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. <i>Immunotherapy</i> , 2011, 3, 487-490.	2.0	3
305	Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time. <i>Oncology Reviews</i> , 2011, 5, 141.	1.8	0
306	Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon- γ for metastatic renal cell cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 553-561.	4.2	22

#	ARTICLE	IF	CITATIONS
307	Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma. <i>Oncology Reviews</i> , 2010, 4, 1-3.	1.8	5
308	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	4.1	1,039
309	Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. <i>Kidney International</i> , 2010, 77, 809-815.	5.2	93
310	Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2010, 36, 16-23.	7.7	46
311	Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET. <i>European Journal of Cancer</i> , 2010, 46, 2432-2440.	2.8	84
312	Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib. <i>World Journal of Hepatology</i> , 2010, 2, 103.	2.0	14
313	Use of Sorafenib in Two Metastatic Renal Cell Cancer Patients with End-Stage Renal Impairment Undergoing Replacement Hemodialysis. <i>Tumori</i> , 2009, 95, 542-544.	1.1	16
314	Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer. <i>Oncology Reviews</i> , 2009, 3, 1-2.	1.8	0
315	Phosphatidylinositol-3-Kinase/Akt Signaling Pathway and Kidney Cancer, and the Therapeutic Potential of Phosphatidylinositol-3-Kinase/Akt Inhibitors. <i>Journal of Urology</i> , 2009, 182, 2569-2577.	0.4	83
316	Tolerability of first-line therapy for metastatic renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2009, 35, 297-307.	7.7	46
317	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	10.7	571
318	Sorafenib tosylate in advanced kidney cancer: past, present and future. <i>Anti-Cancer Drugs</i> , 2009, 20, 409-415.	1.4	19
319	Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. <i>Tumori</i> , 2009, 95, 542-4.	1.1	4
320	How to predict the development of hepatocellular carcinoma in cirrhotic patients. Despite recent advances, the search continues. <i>Oncology Reviews</i> , 2008, 1, 187-188.	1.8	0
321	Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses. <i>Oncology Reviews</i> , 2008, 2, 1-3.	1.8	1
322	The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia. <i>Oncology Reviews</i> , 2008, 2, 67-68.	1.8	0
323	Hepatitis b virus genotype and mutants and the risk of hepatocellular carcinoma. <i>Oncology Reviews</i> , 2008, 2, 129-130.	1.8	0
324	Re: Damien Pouessel, StÃ©phane Culine. High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor. <i>Eur Urol</i> 2008;53:376â€“81. <i>European Urology</i> , 2008, 53, 1092-1093.	1.9	10

#	ARTICLE	IF	CITATIONS
325	Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390.	27.0	12,004
326	Prognostic factors in advanced renal cell cancer. European Journal of Cancer, Supplement, 2008, 6, 35-37.	2.2	1
327	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet, The, 2008, 372, 449-456.	13.7	2,848
328	Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. Clinical Cancer Research, 2008, 14, 541-548.	7.0	65
329	Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics: Targets and Therapy, 2008, 2, 601.	3.2	36
330	Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Oncology Reports, 2008, 20, 1511-9.	2.6	2
331	Bortezomib Inhibits Nuclear Factor- κ B-Dependent Survival and Has Potent In vivo Activity in Mesothelioma. Clinical Cancer Research, 2007, 13, 5942-5951.	7.0	90
332	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax, 2007, 62, 690-695.	5.6	46
333	Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted Agents. Scientific World Journal, The, 2007, 7, 837-849.	2.1	27
334	ASCO 2007: "Translating Research into Practice" Report from the 34th annual meeting of the American Society of Clinical Oncology. Oncology Reviews, 2007, 1, 65-72.	1.8	0
335	Oncology reviews: reasons for a new oncology journal. Oncology Reviews, 2007, 1, 1-2.	1.8	0
336	To fast or not to fast? How food could impact on the absorption of kinase inhibitors and its economical value. Oncology Reviews, 2007, 1, 129-130.	1.8	0
337	Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Research, 2007, 27, 165-73.	1.1	27
338	Adding raltitrexed to cisplatin improves overall survival in people with malignant pleural mesothelioma. Cancer Treatment Reviews, 2006, 32, 229-233.	7.7	5
339	Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemotherapy and Pharmacology, 2006, 59, 149-150.	2.3	59
340	Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site. Cancer, 2006, 107, 2898-2905.	4.1	51
341	Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer. Expert Review of Anticancer Therapy, 2006, 6, 141-152.	2.4	4
342	New Agents in the Management of Advanced Mesothelioma. Seminars in Oncology, 2005, 32, 336-350.	2.2	37

#	ARTICLE	IF	CITATIONS
343	SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure. <i>Cancer Research</i> , 2005, 65, 5256-5262.	0.9	81
344	Autoimmunity in Thrombotic Thrombocytopenic Purpura. <i>Seminars in Thrombosis and Hemostasis</i> , 2005, 31, 633-640.	2.7	9
345	Raltitrexedâ€“Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , 2005, 48, 429-434.	2.0	51
346	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , 2005, 13, 689-95.	2.6	5
347	Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. <i>Oncology Reports</i> , 2005, 14, 113-20.	2.6	19
348	Docetaxel, Carboplatin and Concomitant Radiotherapy for Unresectable Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 155-163.	1.3	15
349	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , 2004, 12, 855-9.	2.6	2
350	Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 359-366.	4.2	30
351	Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone. <i>International Journal of Molecular Medicine</i> , 2003, 11, 161-7.	4.0	6
352	The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 26, 189-193.	2.9	67
353	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: A possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , 2002, 38, 159-162.	2.0	8
354	Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 17-24.	2.3	49
355	Weekly taxanes in metastatic breast cancer (review). <i>Oncology Reports</i> , 2002, 9, 1047-52.	2.6	13
356	Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study. <i>Oncology Reports</i> , 2002, 9, 1107-13.	2.6	6
357	Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 423-428.	2.3	13
358	Interleukin-2 induces cell cycle perturbations leading to cell growth inhibition and death in malignant mesothelioma cells in vitro. <i>Journal of Cellular Physiology</i> , 2000, 185, 126-134.	4.1	18
359	In vitro antioxidant properties of amifostine (WR-2721, Ethyol). <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 45, 172-176.	2.3	58
360	â€“Tunelâ€™ evidence of reduced bone marrow cells apoptosis in a refractory anaemia patient treated with amifostine. <i>British Journal of Haematology</i> , 1999, 104, 424-425.	2.5	6

#	ARTICLE	IF	CITATIONS
361	Cancer Chemotherapy-Related Thrombotic Thrombocytopenic Purpura: Biological Evidence of Increased Nitric Oxide Production. Mayo Clinic Proceedings, 1999, 74, 570-574.	3.0	18
362	EOSINOPHILS AND SERUM EOSINOPHILIC CATIONIC PROTEINS IN INTERLEUKIN-2-BASED IMMUNOTHERAPY FOR CANCER. British Journal of Haematology, 1998, 100, 607-608.	2.5	10
363	Nitrate Plasma Level as a Marker of Nitric Oxide Production After Subcutaneous Interleukin 2 Immunotherapy. Journal of the National Cancer Institute, 1997, 89, 1545-1545.	6.3	7
364	Possible efficacy of allopurinol vaginal washings in the treatment of chemotherapy-induced vaginitis. Cancer Chemotherapy and Pharmacology, 1997, 41, 171-172.	2.3	5
365	Nitrite and Nitrate Plasma Levels, as Markers for Nitric Oxide Synthesis, in Thrombotic Thrombocytopenic Purpura (TTP). Hematology, 1996, 1, 239-246.	1.5	3
366	Thrombotic Thrombocytopenic Purpura and Relapses: Why do case series differ?. American Journal of Hematology, 1996, 52, 215-216.	4.1	3
367	Granulocyte Dysplasia and Dysfunction, and CD11/CD18 Defects in Myelodysplastic Syndromes. Leukemia and Lymphoma, 1996, 23, 267-275.	1.3	20
368	Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer, 1995, 75, 2782-2784.	4.1	3
369	Effect of different platelet agonists on intracellular free CA++ concentrations in human tumor cells: Possible role in tumor growth. International Journal of Cancer, 1995, 62, 291-296.	5.1	7
370	5-Fluorouracil and <i>d, <i>i<i>Leucovorin Calcium Are Active to Treat Unresectable Hepatocellular Carcinoma Patients: Preliminary Results of a Phase II Study. Oncology, 1995, 52, 487-491.	1.9	54
371	HLA-A, B, C, DR and DQ expression and hepatocellular carcinoma: study of 205 Italian subjects. Cancer Letters, 1995, 98, 121-125.	7.2	5
372	Nephrectomy as a component of systemic treatment for renal cell carcinoma patients. Journal of Surgical Oncology, 1994, 56, 81-82.	1.7	0
373	Allopurinol mouthwashes in methotrexate-induced stomatitis. Arthritis and Rheumatism, 1994, 37, 777-778.	6.7	12
374	High-dose human immunoglobulins in thrombotic thrombocytopenic purpura. American Journal of Hematology, 1994, 45, 99-100.	4.1	3
375	Allopurinol Mouthwashes in the Treatment of 5-Fluorouracil-Induced Stomatitis. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 246-247.	1.3	43
376	Anti-HCV Antibodies and Hepatocellular Carcinoma. Upsala Journal of Medical Sciences, 1992, 97, 261-266.	0.9	4
377	Thrombotic thrombocytopenic purpura (TTP): Retrospective study of 84 patients and therapeutic prospects. Transfusion Science, 1992, 13, 39-44.	0.6	12
378	Autoantibody profile in thrombotic thrombocytopenic purpura. Transfusion Science, 1992, 13, 33-36.	0.6	2

#	ARTICLE	IF	CITATIONS
379	TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0
380	Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®). Tumori, 0, , 030089162210995.	1.1	3
381	Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma. Clinical Drug Investigation, 0, , .	2.2	0